TScan Therapeutics
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Domain
tscan.com
Country
United StatesIndustry
BiotechnologyEmployees
101-250
Last Funding
$30.0M
Founded
2017
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does TScan Therapeutics use?+
We have not yet detected technologies for TScan Therapeutics.
What industry is TScan Therapeutics in?+
TScan Therapeutics operates in the Biotechnology industry.
Where is TScan Therapeutics based?+
TScan Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026